Quarterly report [Sections 13 or 15(d)]

Condensed Consolidated Statements of Cash Flows (Unaudited)

v3.26.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Operating Activities    
Net loss $ (5,572) $ (1,965)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 2,134 338
Share-based compensation and restricted stock vesting 277 498
Amortization of right-of-use asset 365 218
Amortization of debt discount 4,584
Changes in fair value of warrant liability and warrant modification expense (6,091) (112)
Loss on issuance of convertible note 824
Changes in operating assets and liabilities:    
Accounts receivable, net (129) 94
Inventory (610) (268)
Prepaid expenses and other assets (231) (263)
Accounts payable 610 34
Accounts payable – related party (116) (110)
Accrued expenses and other current liabilities 861 220
Partnership advance (373) (80)
Operating lease liability (363) (197)
Deferred revenue (2) 1
Net Cash Used in Operating Activities (3,832) (1,592)
Investing Activities    
Capital expenditures (117) (28)
Investment in BioNx (License Agreement) (6,503)
Net Cash Used in Investing Activities (6,620) (28)
Financing Activities    
Proceeds from margin line of credit 1,000
Proceeds from convertible notes payable, net 11,140 1,055
Proceeds from equity offerings (92)
Payment of contingent consideration (178)
Principal payment on financing lease liability (59) (43)
Financing costs (182)
Principal payments of notes payable (847) (71)
Net Cash Provided by (Used in) Financing Activities 10,052 1,671
Net Increase (Decrease) in Cash * (400) 51
Cash and restricted cash – Beginning of period 1,058 1,807
Cash and restricted cash  – End of period 658 1,858
Supplemental Disclosure of Cash Flows Information    
Interest 45 54
Taxes
Supplemental Non-cash Investing and Financing activities    
Issuance of convertible notes and other liabilities in conjunction with license agreement 8,800
Issuance of securities for the conversion of convertible notes payable and accrued interest 1,025
Issuance of warrants in conjunction with convertible notes payable 4,112
Debt issued at a discount 242
Derivative liabilities recognized as debt discounts 11,187
Initial recognition of ROU asset and operating lease liabilities $ 1,617 $ 677